-Ellen Weisberg Researcher Activity Profile

Research Author Detailed Information 

Ellen Weisberg Publication Rate By Year

Ellen Weisberg has published 2 paper(s) in 2006, 4 paper(s) in 2007, 2 paper(s) in 2008, for a total of 8 research publications in total.

Ellen E Weisberg Author Information

LAST NAME: weisberg

FIRST NAME: Ellen

INITIALS: e

AFFILIATION:

Papers

Ellen Weisberg's Publication Record

1. Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells. Year Published: 2006
Department of Medical Oncology, Dana-Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA.
2. Effects of PKC412, nilotinib, and imatinib against GIST-associated PDGFRA mutants with differential imatinib sensitivity. Year Published: 2006
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA. Ellen_weisberg@dfci.harvard.edu
3. Potentiation of antileukemic therapies by Smac mimetic, LBW242: effects on mutant FLT3-expressing cells. Year Published: 2007
Department of Adult Oncology, Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA.
4. An initial pharmacokinetic study with a Metered Dose Transdermal System(R) for delivery of the progestogen Nestorone(R) as a possible future contraceptive. Year Published: 2007
Department of Obstetrics and Gynaecology, University of Sydney, NSW 2006, Australia; Sydney Centre for Reproductive Health Research, Research Division of Family Planning NSW, Ashfield, NSW 2131, Australia.
5. An initial pharmacokinetic study with a Metered Dose Transdermal Systemfor delivery of the progestogen Nestorone as a possible future contraceptive. Year Published: 2007
Department of Obstetrics and Gynaecology, University of Sydney, NSW 2006, Australia. helena@med.usyd.edu.au
6. An initial pharmacokinetic study with a Metered Dose Transdermal Systemfor delivery of the progestogen Nestorone as a possible future contraceptive. Year Published: 2007
Department of Obstetrics and Gynaecology, University of Sydney, NSW 2006, Australia. helena@med.usyd.edu.au
7. Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL- and mutant FLT3-expressing cells. Year Published: 2008
8. Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL- and mutant FLT3-expressing cells. Year Published: 2008
Department of Medical Oncology/Hematologic Neoplasia, Dana-Farber Cancer Institute, Boston, MA 02115, USA.